Search research articles
Contact Us
Filters
Showing results (141-150 of 161) with videos related to
Page
of 17
Sort By:
Cancer Discovery
|
June 14, 2025
Phase Ib basket expansion trial and alternative-schedule dose-escalation study of ATR inhibitor elimusertib in advanced solid tumors with DNA damage response defects
Timothy A Yap, David S P Tan, Anastasios Stathis, et al.
The Oncologist
|
April 24, 2025
Barriers to publishing early phase clinical trials: the oncologists' perspective
Merel J J Lucassen, Pedro Bergmann, Olga Husson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 21, 2026
Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response (DDR) Aberrations: Preclinical and Phase 1b Results
Ezra Y Rosen, Timothy A Yap, Elisa Fontana, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 25, 2019
Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)
Paul Nathan, Paolo A Ascierto, John Haanen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 4, 2019
Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172)
Dirk Schadendorf, Paolo A Ascierto, John Haanen, et al.
Melanoma Research
|
July 31, 2015
Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients
Saif S Ahmad, Wendi Qian, Sarah Ellis, et al.
JCO Global Oncology
|
September 8, 2020
Reimagining Global Oncology Clinical Trials for the Postpandemic Era: A Call to Arms
Kamal S Saini, Begoña de Las Heras, Ruth Plummer, et al.
Nature Medicine
|
June 5, 2023
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results
Timothy A Yap, Elisa Fontana, Elizabeth K Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 27, 2026
Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With <i>BRAF</i> V600-Mutant Solid Tumors
Maria Vieito, Elisa Fontana, Catherine H Han, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 8, 2023
Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study
Yvette Drew, Jae-Weon Kim, Richard T Penson, et al.
Page
of 17
Search research articles
Search
Showing results (141-150 of 161) with videos related to
Sort By:
Page
of 17
Cancer Discovery
|
June 14, 2025
Phase Ib basket expansion trial and alternative-schedule dose-escalation study of ATR inhibitor elimusertib in advanced solid tumors with DNA damage response defects
Timothy A Yap, David S P Tan, Anastasios Stathis, et al.
The Oncologist
|
April 24, 2025
Barriers to publishing early phase clinical trials: the oncologists' perspective
Merel J J Lucassen, Pedro Bergmann, Olga Husson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 21, 2026
Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response (DDR) Aberrations: Preclinical and Phase 1b Results
Ezra Y Rosen, Timothy A Yap, Elisa Fontana, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 25, 2019
Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)
Paul Nathan, Paolo A Ascierto, John Haanen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 4, 2019
Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172)
Dirk Schadendorf, Paolo A Ascierto, John Haanen, et al.
Melanoma Research
|
July 31, 2015
Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients
Saif S Ahmad, Wendi Qian, Sarah Ellis, et al.
JCO Global Oncology
|
September 8, 2020
Reimagining Global Oncology Clinical Trials for the Postpandemic Era: A Call to Arms
Kamal S Saini, Begoña de Las Heras, Ruth Plummer, et al.
Nature Medicine
|
June 5, 2023
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results
Timothy A Yap, Elisa Fontana, Elizabeth K Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 27, 2026
Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With <i>BRAF</i> V600-Mutant Solid Tumors
Maria Vieito, Elisa Fontana, Catherine H Han, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 8, 2023
Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study
Yvette Drew, Jae-Weon Kim, Richard T Penson, et al.
Page
of 17